SILO PHARMA, INC. Proceeds from Sale of Productive Assets
SILO PHARMA, INC. (SILO) reported Proceeds from Sale of Productive Assets of $119.41 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2023-03-24
- SILO PHARMA, INC. proceeds from sale of productive assets for the quarter ending 2021-12-31 was -$136.00, a 100.61% decline year-over-year.
- SILO PHARMA, INC. proceeds from sale of productive assets for the quarter ending 2021-09-30 was $39.24K, a 140.93% increase year-over-year.
- SILO PHARMA, INC. proceeds from sale of productive assets for the quarter ending 2021-06-30 was $50.06K.
- SILO PHARMA, INC. proceeds from sale of productive assets for the quarter ending 2021-03-31 was $30.25K.
- SILO PHARMA, INC. proceeds from sale of productive assets for fiscal 2021 was $119.41K, a 191.78% increase from fiscal 2020.
- SILO PHARMA, INC. proceeds from sale of productive assets for fiscal 2020 was $40.92K.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$136.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $39.10K derived: sum of 2 quarters · filed 2023-03-24 | $89.16K derived: sum of 3 quarters · filed 2023-03-24 | $119.41K 10-K · filed 2023-03-24 |
| 2021-09-30 | $39.24K 10-Q · filed 2021-11-10 | $89.30K derived: sum of 2 quarters · filed 2022-08-01 | $119.54K 10-Q · filed 2022-11-10 | $141.67K derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-06-30 | $50.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $80.31K 10-Q · filed 2022-08-01 | $102.43K derived: sum of 3 quarters · filed 2022-08-01 | $118.72K derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $30.25K 10-Q · filed 2022-05-13 | $52.37K derived: sum of 2 quarters · filed 2022-05-13 | $68.66K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $22.13K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $38.41K derived: sum of 2 quarters · filed 2022-03-28 | $40.92K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $16.29K 10-Q · filed 2021-11-10 | $18.80K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |